Key result
Pimobendan at /kg decreased mean left atrial pressure compared to /kg in dogs with acute mitral valve regurgitation.
Why the study?
Does pimobendan reduce left atrial pressure in dogs with surgically induced mitral valve regurgitation?
Does pimobendan reduce left atrial pressure in dogs with surgically induced mitral valve regurgitation?
Pimobendan dose-dependently decreases left atrial pressure in a canine model of acute mitral regurgitation.
Answers are grounded in this paper and cite their sources.
Supports higher-dose pimobendan for LAP reduction in acute canine MR; hypothesis-generating, requires clinical trials before practice change.
BACKGROUND: The effects of pimobendan on left atrial pressure (LAP) in dogs with mitral valve disease (MR) have not been documented in a quantitative manner. OBJECTIVE: The objective was to document and study the short-term effects of pimobendan on LAP and echocardiographic parameters in MR dogs. ANIMALS: Eight healthy Beagle dogs weighing 10.0-14.7 kg (3 males and 5 females; aged 2 years) were used. METHODS: Experimental, cross-over, and interventional study. Dogs with surgically induced MR received pimobendan at either 0.25 mg/kg or 0.50 mg/kg p.o. q12h for 7 days and then, after a 7-day wash-out period, the other dosage. LAP was measured for 30 minutes at baseline and again on days 1, 2, 4, and 7 of pimobendan administration. RESULTS: Mean LAP was significantly decreased after the administration of 0.25 mg/kg (15.81 ± 5.44 mmHg to 12.67 ± 5.71 mmHg, P < .001) and 0.50 mg/kg (15.76 ± 5.45 mmHg to 10.77 ± 5.23 mmHg, P < .001). Also, the 0.50 mg/kg group led to a significantly lower LAP (P < .01) compared with the 0.25 mg/kg group. Significant reduction was seen for the first time 4 days after the administration of 0.25 mg/kg and a day after the administration of 0.50 mg/kg. CONCLUSIONS AND CLINICAL IMPORTANCE: Pimobendan decreased LAP in a dose-dependent manner in dogs with acute MR caused by experimental chordal rupture. This study did not evaluate adverse effects of high-dose pimobendan, and additional studies in clinical patients are warranted.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2011) studied mitral valve regurgitation (n=8). Pimobendan vs. 0.25 mg/kg p.o. q12h was evaluated on mean left atrial pressure (LAP) (p=<.01). Pimobendan at /kg decreased mean left atrial pressure compared to /kg in dogs with acute mitral valve regurgitation.
Synapse has enriched 10 related papers. Consider them for comparative context: